PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩100 per share · Prices as of the 2026-10-02 close
Ildong Holdings has returned to annual operating profit as core subsidiary Ildong Pharmaceutical normalizes earnings, with the obesity and oncology drug pipeline's licensing and clinical progress as the next watch point.
2025 consolidated operating profit of KRW 14.9bn marked a turnaround after two straight years of losses
Debt ratio improved sharply from around 410% in 2022 to about 132% in 2025
Subsidiary Ildong Pharmaceutical's Q2 2026 operating profit rose sharply year-on-year, sustaining a profit for the cumulative first half
Licensing and clinical entry timelines for the oral GLP-1 obesity candidate and PARP inhibitor are key upcoming pipeline events
Q2 2026 holding-company-level attributable net income stayed near breakeven despite the subsidiary's profit
Ildong Holdings is the holding company of the Ildong Group, established in August 2016 through a spin-off, and does not conduct manufacturing or sales itself; its main revenue sources are investment income (dividends) from subsidiaries, brand royalties, management advisory fees, and rental income.
Its core operating subsidiary is Ildong Pharmaceutical, which manufactures and sells prescription drugs (ETC), over-the-counter drugs (OTC), and health functional foods, and generates most of the group's consolidated results.
Ildong Pharmaceutical's key products are long-running brands such as the Aronamin multivitamin line, Samion, and Furamarin, with OTC items like the Loihi Tsubuko patch also contributing to sales.
Since March 2026, a co-promotion agreement with Viatris Korea for four urology products including Viagra tablets has newly contributed to ETC segment sales.
Drug research and development had been split among group affiliates including Idience (oncology drugs) and Ireed BMS (candidate discovery), but in June 2026 Ildong Pharmaceutical absorbed Yunovia, its dedicated R&D subsidiary, through a no-new-shares small-scale merger, reconsolidating the R&D organization about two and a half years after the spin-off.
The health functional food segment finished clearing distribution inventory in the first half of 2025 and has shown gradual normalization since the second half of that year.
The competitive landscape overlaps with major domestic pharmaceutical companies such as Yuhan, Chong Kun Dang, GC Biopharma, and Hanmi Pharm, and the company's distinguishing feature is running ETC, OTC, and health functional food businesses together as a combined portfolio.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩143B | -₩2.5B | −1.8% |
| 2025Q3 | ₩144.3B | ₩6.1B | 4.2% |
| 2025Q4 | ₩153.8B | ₩7.2B | 4.7% |
| 2026Q1 | ₩148.9B | ₩8.9B | 6.0% |
| 2026Q2 | ₩154B | ₩1.9B | 1.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩675.5B | -₩98.4B | -₩102.4B | −14.6% | −866.4% | 410.1% |
| 2023 | ₩638.4B | -₩79.6B | -₩59.6B | −12.5% | −152.9% | 416.2% |
| 2024 | ₩657.6B | -₩2.4B | ₩63B | −0.4% | 47.1% | 236.5% |
| 2025 | ₩590.9B | ₩14.9B | ₩10.9B | 2.5% | 6.5% | 132.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual results show consecutive large losses in 2022 and 2023: revenue of KRW 675.5bn with an operating loss of KRW 98.4bn (operating margin -14.6%) in 2022, and revenue of KRW 638.4bn with an operating loss of KRW 79.6bn (-12.5%) in 2023.
In 2024, revenue declined to KRW 657.6bn while the operating loss narrowed sharply to KRW 2.4bn (-0.4%), and attributable net profit actually surged to KRW 63.0bn, a result interpreted as reflecting non-operating one-off gains.
In 2025, revenue fell year-on-year to KRW 590.9bn, but the company posted operating profit of KRW 14.9bn (margin 2.5%), turning profitable after two years of losses, with attributable net profit of KRW 10.9bn.
On a quarterly basis, operating profit widened from a loss of KRW 2.5bn in Q2 2025 to gains of KRW 6.1bn in Q3 and KRW 7.2bn in Q4, expanding further to KRW 8.9bn in Q1 2026 before narrowing again to KRW 1.9bn in Q2 2026.
Attributable net profit spiked to KRW 19.3bn in Q4 2025, then fell to KRW 1.4bn in Q1 2026 and to roughly breakeven, near negative KRW 0.02bn, in Q2 2026, showing considerable quarter-to-quarter volatility.
This illustrates a holding-company-specific dynamic in which improvement at operating subsidiary Ildong Pharmaceutical does not translate one-to-one into the holding company's consolidated attributable profit, given minority interest allocations and non-operating items.
Indeed, Ildong Pharmaceutical itself reported Q2 2026 consolidated revenue of KRW 150.9bn (up 9.0% year-on-year) and operating profit of KRW 5.0bn (up 739.1%), with cumulative first-half revenue of KRW 292.9bn and operating profit of KRW 14.2bn (up 197.0%), a clear improvement.
The debt ratio peaked at 416.2% in 2023 after 410.1% in 2022, then steadily declined to 236.5% in 2024 and 132.3% in 2025, indicating ongoing balance-sheet improvement.
In the domestic pharmaceutical industry, competition to expand scale through modified new drugs and co-promotion deals continues in the prescription drug (ETC) market, while OTC and health functional food markets show moderate growth driven by an aging population and rising self-medication demand.
Health functional foods went through a distribution inventory adjustment phase in 2024-2025, with an industry-wide normalization trend observed from the second half of 2025.
Globally, the GLP-1 class of obesity and diabetes treatments is the hottest area in pharma, and Korean pharmaceutical and biotech companies are competing to develop oral small-molecule candidates and secure licensing deals.
Ildong Pharmaceutical's ID110521156 is seeking a global partnership based on Phase 1 clinical results amid this competitive landscape, and the discontinuation of a competing candidate by U.S.-based Terns Pharmaceuticals has been cited as a factor stoking licensing expectations for related companies.
In oncology, the PARP inhibitor Venadaparib is being developed targeting third-line combination therapy for gastric cancer, where differentiation from established global originator PARP inhibitors is key.
The peptic ulcer drug padoprazan, a P-CAB-class treatment, must compete against already-commercialized rival P-CAB products in the domestic market.
Overall, the Ildong Pharmaceutical Group is in a phase where normalization of its core ETC/OTC/health functional food businesses and commercialization progress in its drug pipeline are advancing simultaneously; compared with larger top-tier pharmaceutical companies, its revenue scale is smaller, but market attention is concentrated on the value of its pipeline optionality.
The Ildong Pharmaceutical Group has framed 2026 as a year of two key inflection points: completing a global licensing deal for the oral GLP-1 obesity candidate ID110521156, and advancing the oncology drug Venadaparib into a pivotal registration trial.
According to company interviews, the goal is to finalize a global partner for ID110521156 before entering Phase 2 trials, and given the planned Q1 2027 Phase 2 IND filing, the second half of 2026 is effectively cited as the negotiation deadline.
In Phase 1 trials, the highest 200mg dose produced a placebo-adjusted weight reduction of about 6.8 percentage points over four weeks, and the company said it is considering a 100-150mg range as the appropriate dose for Phase 2.
Venadaparib is reportedly planned to undergo an FDA meeting in the first half of 2026, followed by an IND filing in the second half for a pivotal trial in third-line combination therapy for gastric cancer.
In the ETC segment, growth is expected to be driven by new modified-drug launches, strengthened sales efforts, and expanded co-promotion deals (including Viatris Korea's urology products) planned for 2026, while the health functional food segment is expected to see sales growth following the inventory adjustment.
The company is also simplifying its decision-making structure and pursuing cost efficiencies by reintegrating its R&D organization into Ildong Pharmaceutical through the absorption of Yunovia.
However, the size and timing of any licensing deal, along with the final interpretation of clinical data such as liver function indicators, remain unresolved variables.
The stock's current valuation multiples reflect a changed earnings phase, since such multiples were largely meaningless during the heavy-loss years of 2022-2023 and are now being formed only after the return to profitability.
The shares trade below book value per share, meaning a discount to net asset value, a gap that could shift depending on how the market prices the combined value of the holding company's subsidiary stakes and unrealized pipeline value.
The company has maintained a consistent level of annual cash dividends, and the current dividend yield is generally viewed as below that of other dividend-oriented peers in the sector.
Because of the structural nature of holding company earnings, in which improvement at subsidiary Ildong Pharmaceutical does not translate proportionally into attributable net profit, interpreting earnings multiples requires factoring in quarter-to-quarter volatility.
It is also worth noting that visible progress on pipeline licensing or clinical outcomes could change how the market approaches valuing the company altogether.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After two consecutive years of large operating losses in 2022-2023, the company turned profitable in 2025 with operating profit of KRW 14.9bn. The debt ratio also fell sharply from around 410% in 2022 to about 132% in 2025, clearly easing financial burden.
Subsidiary Ildong Pharmaceutical's Q2 2026 operating profit also rose substantially year-on-year, continuing the core business recovery.
The oral GLP-1 obesity candidate ID110521156 showed meaningful weight-loss efficacy in Phase 1 trials, and the company is pursuing a global partner with the second half of 2026 cited as the effective negotiation deadline.
The PARP inhibitor Venadaparib is also being developed toward entry into a pivotal registration trial for third-line gastric cancer combination therapy. Visible progress on either pipeline could add a new variable to the company's business value.
Since March 2026, the co-promotion agreement with Viatris Korea for urology treatments has newly contributed to ETC segment sales.
In the OTC segment, established brands such as Aronamin and Loihi Tsubuko continue to contribute steadily to sales, while the health functional food segment has entered a normalization phase after inventory adjustment.
Attributable net profit swung sharply from KRW 19.3bn in Q4 2025 to KRW 1.4bn in Q1 2026 and to roughly breakeven in Q2 2026. Because subsidiary earnings improvement does not translate proportionally into the holding company's consolidated figures, interpreting quarterly results requires caution.
The 2025 operating margin was only 2.5%, and the company posted an operating loss as recently as 2024, meaning that even with the return to profit, margin cushion remains thin. Revenue itself has declined from KRW 675.5bn in 2022 to KRW 590.9bn in 2025.
The GLP-1 candidate has only completed Phase 1 trials, and both the timing and terms of any licensing deal remain uncertain, with the possibility that negotiations could be delayed or fall short of expectations.
Venadaparib is also at an early stage ahead of entering a pivotal registration trial, and full commercialization could require considerable additional time and capital.
The global partnership for ID110521156 is cited as effectively facing a negotiation deadline in the second half of 2026, but there is a risk the deal may not materialize or its terms may fall short of expectations.
Interpretation of liver-function-related indicators, including bilirubin changes in clinical data, could affect negotiations with potential partners. The timeline for Venadaparib's IND filing and pivotal trial progress could also change depending on the outcome of regulatory discussions.
ETC, OTC, and health functional food sales are exposed to external variables such as government drug pricing policy, health insurance reimbursement standards, and competitor product launches.
The possibility that new revenue sources such as co-promotion agreements could shrink again due to contract changes or termination cannot be ruled out.
Although the debt ratio has fallen sharply, it remains above 100%, leaving sensitivity to interest rates and subsidiary performance.
Given the holding company structure, non-controlling interests account for a share similar to or larger than the controlling interest, meaning the structural characteristic in which subsidiary profits are not fully attributed to controlling shareholders is likely to persist.
Watch for whether a global licensing deal for ID110521156 is finalized and on what terms during this window. If the negotiation deadline the company referenced passes, it is also worth checking whether the Phase 2 IND filing plan and partnership strategy change.
Check whether Venadaparib's IND filing for a pivotal third-line gastric cancer combination trial is submitted. If it is filed, it will also be worth reviewing whether the development roadmap becomes more concrete following entry into the pivotal trial.
Check the preliminary Q3 2026 earnings disclosures for both Ildong Pharmaceutical and Ildong Holdings. Key points to watch are whether the holding company's attributable net profit, which narrowed in Q2, recovers, and whether the subsidiary's operating profit improvement continues.
Check whether the health functional food segment's sales growth actually continues after the inventory adjustment, and whether the contribution of co-promotion and modified new drug sales to the ETC segment expands.
Ildong Holdings has moved past the large losses of 2022-2023 into a phase combining a return to annual operating profit in 2025 with an improved debt ratio.
However, due to the structural nature of a holding company, quarterly attributable net profit has fluctuated significantly independent of the subsidiary's earnings improvement, staying at roughly breakeven in Q2 2026.
Core subsidiary Ildong Pharmaceutical continues to improve results, supported by new co-promotion revenue and steady sales from established brands.
Over the medium to long term, progress on licensing and clinical development for the oral GLP-1 obesity candidate and the oncology drug Venadaparib stand out as variables that could reshape the company's business value.
The current share price trades below net asset value, which can be interpreted as reflecting both earnings volatility and pipeline uncertainty together. Investors will want to monitor both the upcoming third-quarter results and concrete progress on the drug pipeline.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.